GSK and Amgen - Top 5 Emerging Market Deals

Who: GlaxoSmithKline
With: Amgen
Where: China, Brazil and India

Deal Size: $120 million

Details: A year before Amgen won approval of denosumab for postmenopausal women with osteoporosis, GlaxoSmithKline snagged marketing rights for the drug in China, Brazil and India--three of the largest emerging pharmaceutical markets. Additionally, GSK got rights to sell the drug in South Korea and all other markets where Amgen doesn't have a commercial presence.

Amgen and GSK also agreed to share commercialization of denosumab in Europe, Australia, New Zealand and Mexico. The Big Biotech got an initial payment and near-term commercial milestones to Amgen totaling $120 million, and ongoing royalties. Analysts estimate the drug could eventually reach up to $2 billion in annual sales.

GSK and Amgen - Top 5 Emerging Market Deals

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.